SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324 [Yahoo! Finance]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Yahoo! Finance
SAGE announced that partner Biogen BIIB has terminated its rights related to the investigational neurology candidate, SAGE-324. A phase II study on SAGE-324 for treating essential tremor (ET) failed to meet the primary endpoint in July. The termination will be effective from Feb. 17, 2025. Following the termination of the deal by BIIB, Sage Therapeutics will obtain full ownership and rights of SAGE-324. The company plans to study SAGE-324 for other indications, if any. Year to date, shares of Sage Therapeutics have plunged 66.9% compared with the industry's decrease of 1.9%. Image Source: Zacks Investment Research SAGE's Licensing Agreement With BIIB In July, Sage Therapeutics and Biogen announced top-line data from the phase II KINETIC 2 study, which evaluated SAGE-324 as a potential treatment for ET. The study failed to demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with ET. Based on the disappointing data, SA
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics, Inc. Lawsuit – SAGEAccesswire
- Sage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGEAccesswire
- Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)GlobeNewswire
- Class Action Filed Against Sage Therapeutics, Inc. (SAGE) - October 28, 2024 Deadline to Join - Contact Levi & KorsinskyAccesswire
- Sage Therapeutics, Inc Is Being Sued For Violating Securities Laws And Investors Are Encouraged To Help The Schall Law Firm Accesswire
SAGE
Earnings
- 7/31/24 - Miss
SAGE
Sec Filings
- 9/26/24 - Form 8-K
- 9/17/24 - Form S-3ASR
- 8/7/24 - Form 4
- SAGE's page on the SEC website